ES2172675T3 - Utilizacion de difosfonatos sustituidos con fenol como agentes antineoplasticos. - Google Patents
Utilizacion de difosfonatos sustituidos con fenol como agentes antineoplasticos.Info
- Publication number
- ES2172675T3 ES2172675T3 ES96928381T ES96928381T ES2172675T3 ES 2172675 T3 ES2172675 T3 ES 2172675T3 ES 96928381 T ES96928381 T ES 96928381T ES 96928381 T ES96928381 T ES 96928381T ES 2172675 T3 ES2172675 T3 ES 2172675T3
- Authority
- ES
- Spain
- Prior art keywords
- sup
- sub
- group
- zero
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/404—Esters of poly(thio)phosphonic acids containing hydroxy substituents in the hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA INVENCION PRESENTA LA APLICACION DE UN GEM-DIFOSFONATO SUBSTITUIDO CON UN FENOL ELEGIDO ENTRE LOS COMPUESTOS DE FORMULA (I), EN LA QUE Z SUP,1}, Z SUP,2}, Z SUP,3} Y Z SUP,4} SON IGUALES O DIFERENTES Y SON OR, SIENDO R H, UN GRUPO ALQUILO CICLICO, RAMIFICADO O LINEAL QUE COMPRENDE DE 1 A 8 ATOMOS DE CARBONO, OM, SIENDO M UN CATION, NR SUB,2}, TENIENDO R EL MISMO SIGNIFICADO ANTERIORMENTE DEFINIDO, Z SUP,1}, Z SUP,2}, Z SUP,3} Y Z SUP,4} PUEDEN FORMAR UN ANILLO ALQUILIDENODIOXILO QUE COMPRENDA DE 2 A 8 ATOMOS DE CARBONO, X SUP,1}, X SUP,2} SON IDENTICOS O DIFERENTES Y SON H, UN ATOMO DE HALOGENO, UN GRUPO ALCOXILO O ALQUILO CICLICO, RAMIFICADO O LINEAL DE 1 A 8 ATOMOS DE CARBONO, X SUP,3} ES H, UN GRUPO ALQUILO R SUP,1} DE 1 A 4 ATOMOS DE CARBONO, UN GRUPO ACILO C(O)R SUP,1}, UN GRUPO CARBAMILO C(O)NHR SUP,1}, SIENDO R SUP,1} EL DESCRITO ANTERIORMENTE, X SUP,3}O Y UNO DE LOS DOS RESTANTES SUBSTITUYENTES X SUP,1} O X SUP,2} PUEDEN FORMAR UN ANILLO ALQUILIDENODIOXILO QUE COMPRENDA DE 1 A 4ATOMOS DE CARBONO, A ES -CH=CH-CH SUB,2}-, -(CH SUB,2}) SUB,N}-, -S-, -SO SUB,2}-, -S(CH SUB,2}) SUB,N}-, -SO SUB,2}(CH SUB,2}) SUB,N}-, SIENDO N UN NUMERO ENTERO DE 1 A 7 O BIEN FORMAR CON B UN GRUPO ALQUILIDENO DE FORMULA -(CH-CH) SUB,K}-(CH SUB,2}) SUB,D}-CH= EN LA QUE K ES CERO O 1 Y D ES UN NUMERO ENTERO DE CERO A 4, B ES H, UN GRUPO ALQUILO DE 1 A 4 ATOMOS DE CARBONO, T ES CERO O 1, CON LA CONDICION DE QUE T SEA CERO SOLO CUANDO A SEA (CH-CH) SUB,K}(CH SUB,2}) SUB,D}-CH= SIENDO K Y D COMO SE DESCRIBEN ANTERIORMENTE, PARA FABRICAR UN MEDICAMENTO PARA EL TRATAMIENTO O LA PREVENCION DE ENFERMEDADES NEOPLASICAS Y, EN PARTICULAR, PARA CANCERES DEPENDIENTES DE RAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH02213/95A CH690163A5 (fr) | 1995-07-28 | 1995-07-28 | Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2172675T3 true ES2172675T3 (es) | 2002-10-01 |
Family
ID=4228513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96928381T Expired - Lifetime ES2172675T3 (es) | 1995-07-28 | 1996-07-26 | Utilizacion de difosfonatos sustituidos con fenol como agentes antineoplasticos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6127350A (es) |
| EP (1) | EP0845991B1 (es) |
| JP (1) | JPH11511127A (es) |
| CN (1) | CN1091601C (es) |
| AT (1) | ATE212847T1 (es) |
| AU (1) | AU723094B2 (es) |
| CA (1) | CA2228212A1 (es) |
| CH (1) | CH690163A5 (es) |
| DE (1) | DE69619117T2 (es) |
| DK (1) | DK0845991T3 (es) |
| ES (1) | ES2172675T3 (es) |
| PT (1) | PT845991E (es) |
| WO (1) | WO1997004785A1 (es) |
| ZA (1) | ZA966364B (es) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9603637D0 (en) * | 1996-02-21 | 1996-04-17 | Smithkline Beecham Plc | Process |
| EP0998934A4 (en) * | 1997-12-25 | 2005-09-14 | Toray Industries | REMEDIES AGAINST INTRAMEDULLARY DISEASES |
| CA2747954C (en) | 1999-12-03 | 2014-02-25 | The Regents Of The University Of California | Phosphonate compounds |
| GB0019272D0 (en) * | 2000-08-04 | 2000-09-27 | Symphar Sa | Pharmaceutical compounds |
| FR2827289B1 (fr) * | 2001-07-16 | 2004-07-23 | Univ Paris 13 | Nouveau derive d'acide diphosphonique, son application en therapeutique et procede de preparation |
| ES2336312T3 (es) | 2001-07-16 | 2010-04-12 | Universite Paris 13 | Procedimiento de preparacion de derivados de bisfosfonatos. |
| JP2005511526A (ja) * | 2001-10-18 | 2005-04-28 | イレックス プロダクツ インコーポレイテッド | ジホスホネート誘導体による皮膚の治療方法 |
| EP1506208A4 (en) * | 2002-05-11 | 2006-05-24 | Ilex Products Inc | 1,1- AND 1,2-BISPHOSPHONATES AS MODULATORS OF APOLIPOPROTEIN E |
| JP2006503023A (ja) * | 2002-09-03 | 2006-01-26 | バイオヴェイル ラボラトリーズ インコーポレイテッド | スタチン薬物の放出調節ための医薬品製剤および方法 |
| WO2004026242A2 (en) * | 2002-09-19 | 2004-04-01 | Ilex Oncology Research, Sarl | Substituted ketophosphonate inhibitors of tumor cell proliferation |
| ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2649288C (en) | 2006-04-19 | 2015-11-24 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| AU2008254425A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| PE20121172A1 (es) | 2009-10-14 | 2012-09-05 | Merck Sharp & Dohme | Piperidinas sustituidas con actividad en la hdm2 |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| US8987275B2 (en) | 2010-03-16 | 2015-03-24 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| US9029341B2 (en) | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| EP3400943B1 (en) * | 2012-03-23 | 2020-12-02 | Array Biopharma, Inc. | Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| KR102196882B1 (ko) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Hdm2 억제제로서의 치환된 이미다조피리딘 |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| EP3209671B8 (en) | 2014-10-21 | 2019-07-31 | Council of Scientific and Industrial Research | Alkylidene phosphonate esters as p-glycoprotein inducers |
| JP6854762B2 (ja) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤 |
| USRE50776E1 (en) | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CN106986789B (zh) * | 2016-01-20 | 2019-07-16 | 中国人民解放军军事医学科学院生物医学分析中心 | 对苯二酚类化合物及其制备方法与在抗肿瘤或免疫调节中的应用 |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| EP3525785B1 (en) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| KR102702926B1 (ko) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
| EP3706747B1 (en) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US12552826B2 (en) | 2018-08-07 | 2026-02-17 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| BR112022012015A2 (pt) | 2019-12-17 | 2022-08-30 | Merck Sharp & Dohme Llc | Inibidores de prmt5 |
| US12441730B2 (en) | 2019-12-17 | 2025-10-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2021126731A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP4673747A1 (en) | 2023-03-02 | 2026-01-07 | CARCIMUN BIOTECH GmbH | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH675422A5 (es) * | 1988-03-31 | 1990-09-28 | Symphar Sa | |
| JPH0377894A (ja) * | 1989-08-18 | 1991-04-03 | Toray Ind Inc | メチレンジホスホン酸化合物 |
-
1995
- 1995-07-28 CH CH02213/95A patent/CH690163A5/fr not_active IP Right Cessation
-
1996
- 1996-07-26 AT AT96928381T patent/ATE212847T1/de not_active IP Right Cessation
- 1996-07-26 DE DE69619117T patent/DE69619117T2/de not_active Expired - Fee Related
- 1996-07-26 ZA ZA966364A patent/ZA966364B/xx unknown
- 1996-07-26 AU AU67874/96A patent/AU723094B2/en not_active Ceased
- 1996-07-26 CN CN96196005A patent/CN1091601C/zh not_active Expired - Fee Related
- 1996-07-26 CA CA002228212A patent/CA2228212A1/en not_active Abandoned
- 1996-07-26 WO PCT/EP1996/003301 patent/WO1997004785A1/en not_active Ceased
- 1996-07-26 DK DK96928381T patent/DK0845991T3/da active
- 1996-07-26 EP EP96928381A patent/EP0845991B1/en not_active Expired - Lifetime
- 1996-07-26 US US09/011,247 patent/US6127350A/en not_active Expired - Fee Related
- 1996-07-26 JP JP9507232A patent/JPH11511127A/ja active Pending
- 1996-07-26 ES ES96928381T patent/ES2172675T3/es not_active Expired - Lifetime
- 1996-07-26 PT PT96928381T patent/PT845991E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU723094B2 (en) | 2000-08-17 |
| CN1192148A (zh) | 1998-09-02 |
| JPH11511127A (ja) | 1999-09-28 |
| EP0845991A2 (en) | 1998-06-10 |
| PT845991E (pt) | 2002-07-31 |
| DE69619117T2 (de) | 2002-09-19 |
| DE69619117D1 (de) | 2002-03-21 |
| CA2228212A1 (en) | 1997-02-13 |
| CH690163A5 (fr) | 2000-05-31 |
| HK1015686A1 (en) | 1999-10-22 |
| ZA966364B (en) | 1997-02-11 |
| WO1997004785A1 (en) | 1997-02-13 |
| AU6787496A (en) | 1997-02-26 |
| DK0845991T3 (da) | 2002-05-27 |
| CN1091601C (zh) | 2002-10-02 |
| EP0845991B1 (en) | 2002-02-06 |
| US6127350A (en) | 2000-10-03 |
| ATE212847T1 (de) | 2002-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2172675T3 (es) | Utilizacion de difosfonatos sustituidos con fenol como agentes antineoplasticos. | |
| CY1105399T1 (el) | Μεθοδος επιλεκτικης υποκαταστασεως των ταξανων | |
| BR0302407A (pt) | Núcleo envolvido | |
| DE59203597D1 (de) | Härtbare organo(poly)siloxanmassen. | |
| MIWA et al. | Evaluation of the TNM classification of stomach cancer and proposal for its rational stage-grouping | |
| AR002039A1 (es) | Pirido[3.2-e]pirazinonas con efecto antiasmatico, y procedimiento para su preparacion y los medicamentos que los contienen y su preparación | |
| HRP20000791B1 (en) | Platinum complex, its preparation and therapeutic application | |
| ES2068008T3 (es) | Composicion de lavado. | |
| SE8702563L (sv) | Farmaceutiska kompositioner | |
| ES2182114T3 (es) | Derivados azabiciclicos de la carbamoiloxi-multilina para empleo antibacteriano. | |
| AR033957A1 (es) | Nuevos compuestos | |
| ATE135359T1 (de) | Sulfoniumsalze und verfahren zu deren herstellung | |
| ES2116612T3 (es) | Nuevas bis-naftalimidas para el tratamiento del cancer. | |
| CA2069638A1 (en) | Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands | |
| KR910007531A (ko) | 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료 | |
| JPS53137644A (en) | Managing system for hospital information | |
| IT9019793A0 (it) | Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico | |
| ES2172294T3 (es) | Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| JPS53137643A (en) | Managing system for hospital information | |
| ATE118004T1 (de) | 4-amidino-chroman und 4-amidino-pyrano(3,2- c)pyridinderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen. | |
| BR9913321A (pt) | Medicamento contendo compostos de complexos de platina, assim como sua aplicação | |
| MX174093B (es) | 1,1-DIOXIDOS DE 3,4-DIHIDRO-2-ALQUIL-3-OXO-N-ARIL-2H[1] BENZOTIENO[3,2-e]-1,2-TIAZINO-4-CARBOXIAMIDA | |
| ATE145647T1 (de) | Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen | |
| ATE96025T1 (de) | Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin. | |
| ES2081884T3 (es) | Factor citotoxico oligodendrocitico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 845991 Country of ref document: ES |